

(12) United States Patent

Jain et al. (45) Date of Patent: US 9,408,806 B2

(10) **Patent No.:**

*Aug. 9, 2016

(54) TABLET DOSAGE FORM

(71) Applicants: Girish Kumar Jain, Delhi (IN);

Ramakant Gundu, Ahmednagar (IN);

Rahul Dabre, Nagpur (IN)

Inventors: Girish Kumar Jain, Delhi (IN);

Ramakant Gundu, Ahmednagar (IN);

Rahul Dabre, Nagpur (IN)

(73) Assignee: Wockhardt Limited, Bandra East,

Mumbai (IN)

(*) Notice: Subject to any disclaimer, the term of this

patent is extended or adjusted under 35

U.S.C. 154(b) by 0 days.

This patent is subject to a terminal dis-

claimer.

(21) Appl. No.: 14/026,106

(22)Filed: Sep. 13, 2013

Prior Publication Data (65)

Mar. 19, 2015 US 2015/0079170 A1 US 2016/0213620 A9 Jul. 28, 2016

Related U.S. Application Data

(63) Continuation of application No. 12/602,168, filed as application No. PCT/IB2008/051092 on Mar. 25, 2008, now Pat. No. 8,574,625.

(30)Foreign Application Priority Data

May 30, 2007	(IN)	1006/2007
Mar. 19, 2008	(IN)	558/2008

(51) Int. Cl.

(2006.01)
(2006.01)
(2006.01)
(2006.01)
(2006.01)

A61K 45/06 (2006.01)A61K 31/196 (2006.01)A61K 31/4422 (2006.01)A61K 31/5575 (2006.01)

(52) U.S. Cl.

CPC A61K 9/2886 (2013.01); A61K 31/196 (2013.01); A61K 31/40 (2013.01); A61K 31/4184 (2013.01); A61K 31/4418 (2013.01); A61K 31/4422 (2013.01); A61K 31/55 (2013.01); A61K 31/5575 (2013.01); A61K 45/06 (2013.01)

Field of Classification Search

None

See application file for complete search history.

(56)References Cited

U.S. PATENT DOCUMENTS

7,871,643 B2*	1/2011	Lizio et al	424/452
2005/0222136 A1*	10/2005	Buschmann et al	514/221

FOREIGN PATENT DOCUMENTS

EP	1020182	*	1/2000	 A61K 9/20
WO	WO 00/01368	*	1/2000	 A61K 9/26

^{*} cited by examiner

Primary Examiner — Jake Vu

(74) Attorney, Agent, or Firm — Bio Intellectual Property Services LLC (Bio IPS);O. (Sam) Zaghmout

ABSTRACT (57)

The present invention relates to novel tablet dosage forms and methods of preparing these forms, which can be used for different classes of pharmaceutical active ingredients posing stability issues in a single unit system. The dosage form includes a first layer, which includes a tablet of one or more active pharmaceutical ingredients, which is inlayed in the first layer along with other pharmaceutically acceptable excipients, and a second layer that includes one or more active pharmaceutical ingredients optionally with other pharmaceutically acceptable excipients.

9 Claims, 2 Drawing Sheets